NASDAQ:FUSN - Fusion Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $23.67
  • Forecasted Upside: 180.41 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$8.44
▼ -0.27 (-3.10%)
1 month | 3 months | 12 months
Get New Fusion Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FUSN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FUSN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$23.67
▲ +180.41% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Fusion Pharmaceuticals in the last 3 months. The average price target is $23.67, with a high forecast of $25.00 and a low forecast of $21.00. The average price target represents a 180.41% upside from the last price of $8.44.
Buy
The current consensus among 5 investment analysts is to buy stock in Fusion Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/19/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/13/2021Morgan StanleyLower Price TargetOverweight$23.00 ➝ $21.00N/A
i
4/6/2021Morgan StanleyLower Price TargetOverweight$23.00 ➝ $21.00Low
i
12/17/2020Bloom BurtonReiterated RatingBuyMedium
i
Rating by A. Borovina at Bloom Burton
7/21/2020Morgan StanleyInitiated CoverageOverweight$23.00High
i
7/21/2020Jefferies Financial GroupInitiated CoverageBuy$25.00High
i
7/21/2020WedbushInitiated CoverageOutperform$25.00High
i
Rating by D. Nierengarten at Wedbush
7/21/2020CowenInitiated CoverageOutperformHigh
i
(Data available from 4/19/2016 forward)
Fusion Pharmaceuticals logo
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
Read More

Today's Range

Now: $8.44
$8.29
$9.22

50 Day Range

MA: $10.88
$8.64
$12.15

52 Week Range

Now: $8.44
$8.29
$19.00

Volume

22,500 shs

Average Volume

53,049 shs

Market Capitalization

$353.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Fusion Pharmaceuticals?

The following equities research analysts have issued stock ratings on Fusion Pharmaceuticals in the last twelve months: Bloom Burton, Cowen Inc, Jefferies Financial Group Inc., Morgan Stanley, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for FUSN.

What is the current price target for Fusion Pharmaceuticals?

3 Wall Street analysts have set twelve-month price targets for Fusion Pharmaceuticals in the last year. Their average twelve-month price target is $23.67, suggesting a possible upside of 180.4%. Jefferies Financial Group Inc. has the highest price target set, predicting FUSN will reach $25.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $21.00 for Fusion Pharmaceuticals in the next year.
View the latest price targets for FUSN.

What is the current consensus analyst rating for Fusion Pharmaceuticals?

Fusion Pharmaceuticals currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe FUSN will outperform the market and that investors should add to their positions of Fusion Pharmaceuticals.
View the latest ratings for FUSN.

What other companies compete with Fusion Pharmaceuticals?

How do I contact Fusion Pharmaceuticals' investor relations team?

Fusion Pharmaceuticals' physical mailing address is 270 LONGWOOD ROAD SOUTH, HAMILTON A6, L8P 0A6. The company's listed phone number is 289-799-0891 and its investor relations email address is [email protected] The official website for Fusion Pharmaceuticals is fusionpharma.com.